Los Angeles-based Puma Biotechnology Inc.’s FDA-approved Nerlynx (neratinib) tablets — a kinase inhibitor developed to treat breast cancer — will be circulated by Biologics Inc. as per a limited distribution agreement between the companies.
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, specifically following treatment with trastuzumab, according to McKesson spokespersons.
“We are pleased to be part of the distribution network for Nerlynx, as this promising agent provides oncologists a new treatment option for HER2-positive patients who remain at significant risk for disease recurrence after targeted therapy,” Brandon Tom, vice president of Biopharma Services for McKesson Specialty Health, said. “As prospects are poor for HER2-positive patients whose disease returns, any therapy that reduces the risk of recurrence is a welcome addition to the treatment options.”
As an oncology specialist, Biologics uses a “high-touch care model” emphasizing a team approach to the patient’s experience. The company emphasizes the individual’s specific medical, financial and psychosocial needs to deliver optimum treatment plans. Relying on communication, each team includes a knowledgeable pharmacist and oncology nurse and an experienced financial counselor, ensuring a patient-centric care model.
Biologics Inc. of Cary, North Carolina, is a division of McKesson Corp.